In a recent study published in the Journal of Biomedical Optics, researchers from the Indian Institute of Technology Indore unveiled a groundbreaking advancement—a compact and cost-effective PA sensing instrument designed specifically for biomedical tissue diagnosis. This proof-of-concept study employs low-cost diode laser. It represents a crucial step towards bridging the gap between laboratory research and clinical applications. The newly developed instrument integrates multiple laser diodes within a compact casing, alongside a custom-built pulsed current supply unit. This setup ensures efficient PA excitation, generating precise 25 nanosecond pulses at a frequency of 20 kHz. Subsequent data analysis involved calculating frequency spectra to quantitatively assess tissue properties. The results revealed distinct spectral patterns corresponding to different tissue types. For instance, fibrocystic breast disease exhibited a dominant frequency peak around 1.60 MHz, indicative of increased tissue density due to heightened glandular and stromal… 

COPENHAGEN, Denmark, February 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today reports preliminary, unaudited financial results for 2023 and financial guidance for 2024. Furthermore, the Company provides an update on its R&D priorities. The post Bavarian Nordic delivered record financial results in 2023 appeared first on Bio Tech Winners. Bavarian Nordic delivered record financial results in 2023

Will it soon be possible to inhale medicine easily? Researchers have now successfully tested a potentially revolutionary nanomaterial on humans for the first time. They describe it as a "wonder material." Tests with face masks The scientists led by Dr. Mark Miller from the Center for Cardiovascular Science at the University of Edinburgh used for this first study, published in the journal Nature, [...] Researchers test "wonder material" safely on humans for the first time

For orphan drugs, the political goal of aligning the price with the additional benefit is only achieved through the subsequent regular benefit assessment. This is shown by a current IQWiG analysis. To promote the development of drugs for rare diseases (orphan drugs) despite economic risks, they are treated preferentially in Germany: New orphan drugs only have to demonstrate an additional benefit compared to the appropriate comparator therapy if they exceed the annual sales limit of 30 million euros (up to November 2022: 50 million euros). Previously, their additional benefit is considered proven, and the Gemeinsame Bundesausschuss (G-BA) merely quantifies the extent of the additional benefit based on the (marketing authorization) documents. If, within the scope of this "limited assessment," no classification into the categories "minor," "considerable," or "substantial" is possible, the G-BA must still attest a "non-quantifiable" additional benefit to the active ingredient. The Institute for Quality and Efficiency in Health Care (IQWiG) has now analyzed the impact of this preferential treatment of orphan drugs on the prices of...